FDA advisors recommend Eli Lilly Alzheimer's drug donanemab
If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
Source: cnbc.com
Mark Mintun News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Mintun Today - Breaking & Trending Today
Inside the plan to diagnose Alzheimer's in people with no memory problems — and who stands to benefit
People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.
Source: yahoo.com
The plan to diagnose Alzheimer's in people with no memory problems
People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.
Source: latimes.com
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety risk
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more
Source: stltoday.com
Promising new Alzheimer's drugs may benefit Whites more than Blacks
Older Black Americans have twice the rate of dementia as Whites
Source: dunyanews.tv